How data science is driving genomics in the pharmaceutical industry
In this article, Ramya Sriram describes how data science is driving innovations in medical biotechnology and genomics.
List view / Grid view
Articles
COVID-19 drug development based on boosting immunity
Baidyanath Dash explains the two requirements for COVID-19 drug development: killing the virus and boosting immunity.
A computational effort to deciphering putative COVID-19 3C-like protease binders
Dr Isaac Karimi and his team explain how compounds to treat COVID-19 could be found in Kurdish ethnomedicine, selecting some plants for computational drug discovery.
Unlocking the power of the microbiome in life sciences R&D
Anthony Finbow explains how applying microbiome-based evidence to disease modelling will enable researchers to devise more targeted treatments.
Human 3D cell-based systems to research gout: drug discovery for a neglected disease
In this article Andrew Nyborg from Horizon Therapeutics discusses why researchers are taking a second look at gout and how they are modelling the condition, which is unique to humans.
RNA sequencing provides insights into why every SARS-CoV-2 infection is different
Associate Professor Pandurangan Vijayanand from La Jolla Institute for Immunology discusses his study into the body’s immune response to SARS-CoV-2 and why this can vary.
The Editors’ views: Drug Target Review’s 2020 round-up
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
Trends in pancreatic cancer literature – findings from Elsevier
In a new report, Elsevier describes how it used text mining to reveal the top trends in pancreatic cancer research – this article outlines the findings.
Combining deep computational learning and synthetic biology
Dr Diogo Camacho from the Wyss Institute at Harvard discusses new research into using machine learning algorithms to analyse RNA sequences and reveal potential drug targets.
Advancing CHO cell line engineering with CRISPR
Chinese hamster ovary (CHO) cell lines are a firm favourite with biologics companies because of the extensive developmental work undertaken in recent decades. In this article, Junrui Li divulges how CRISPR technology is now being employed to further enhance productivity.
Tracking SARS-CoV-2 with genome sequencing
Researchers have been tracking SARS-CoV-2 by sequencing the genomes of virus samples collected from diagnostic testing. They hope that using next-generation sequencing (NGS) on SARS-CoV-2 will help to accurately diagnose the novel coronavirus, identify mutations and track its history. This article explores the findings of their latest study and what…
A label-free imaging technique for drug evaluation at single‑cell level
This article provides a brief overview of the technical and conceptual advantages of Raman spectroscopy, a label-free imaging technique that is being increasingly used for the purpose of drug evaluation.
Biosynthetic polysaccharide-based drugs and nutraceuticals from non-animal sources
Glycosaminoglycans (GAGs) are a class of naturally occurring polysaccharides that play vital roles in cellular functions. GAGs (eg, hyaluronic acid, heparosan, chondroitin, chondroitin sulfate, heparan sulfate and heparin) have also been utilised in biopharmaceutical and nutraceutical industries. Animal-sourced GAGs can contain process impurities and contaminants, which may result in adverse…
Genetic screening to predict the risk of future diseases
The use of genetic testing has had a positive impact on patient care, bringing abundant opportunities for diagnosis or predictions of future diagnoses. Pushpanathan Muthuirulan explains how the application of genetic screening can help to customise healthcare for individuals based on their unique genetic makeup.
Predicting COVID-19 susceptibility and severity
Recent reports suggest that both clinical and genetic risk factors may contribute to COVID-19 susceptibility and severity. Catherine Ball, Chief Scientific Officer of Ancestry®, discusses results of the company’s COVID-19 Research Study, designed to explore non-genetic and genetic associations with disease outcomes.
